The deregulation of LPAR1, including the function and levelof expression, is linked to cancer initiation, progression, and metastasis.LPAR1 antagonists, AM095 or Ki16425, may be effective therapeuticmolecules, yet their limited water solubility hinders in vivo delivery.In this study, we report on the synthesis of two liposomal formulationsincorporating AM095 or Ki16425, embedded within the lipid bilayer,as targeted nanocarriers for metastatic breast cancer (MBC). This evidence concerns the gene LPAR1 and cancer.